Drug repositoning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs

Abstract

<jats:title>ABSTRACT</jats:title><jats:p>Drug repositioning aims to find new indications for existing drugs, in order to reduce drug development cost and time. Currently, numerous successful stories of drug repositioning have been reported and many drugs are already available on the market. Although many of those cases are products of serendipitous findings, repositioning opportunities can be uncovered systematically by following either a disease-centric approach, as a result of a close relation between an old and new indication, a target-centric one, which links a known target and its established drug to a new indication, or a drug-centric approach, which connects a known drug to a new target and its associated indication. The three approaches differ in their complexity, potential, and limits, and most important the necessary starting information and computational power. Which one is predominant in current drug repositioning and what does this imply for future developments? To address these questions, we systematically evaluated over 100 drugs, 200 targets structures and over 300 indications from the Drug Repositioning Database. Each of the analysed cases has been classified based on one of the three repositioning approaches, showing that the majority, more than 60%, falls within the disease-centric definition, around 30% within the target-centric, and only less than 10% within the drug-centric. We therefore concluded that so far repositioning has mainly been disease and target repositioning and not, as drug repositioning, as expected by definition. We discuss the reasons and suggest directions to exploit the full potential of techniques useful for drug-centric in order to sustain future rationale repositioning pipelines.</jats:p>

Natural product drug discovery in the artificial intelligence era

“…Beyond shing the biological targets of NPs, de-orphanizing ML approaches provide new opportunities for drug repurposing/ repositioning. 270,271 Generating de novo natural productinspired compounds…”

Structure-based drug repositioning: Potential and limits

“…The diseases might be closely related, the drug's target may play a role in two different diseases, or the drug has two targets each linked to a different disease (see Figure 3 ). These approaches were introduced by Parisi et al as disease-, target-, and drug-centric 56 . Disease-centric repositioning A focus on disease is the most direct approach, since it is driven by the hypothesis that a drug's use can be expanded from the original to a closely related indication.…”

Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges

“…Target-based approach links a known target and its established drug to a new indication. However, it requires a deep understanding of the molecular relationship between the target and the disease [ 29 ]. Knowledge-based approaches consolidate known information about a drug to anticipate previously unexplored mechanisms including presence of unidentified drug targets for old drugs, undiscovered drug–drug similarities and new biomarkers [ 23 ].…”